Inleiding richtlijn de ziekte van Parkinson - Medisch Contact

(134) Macleod AD, Counsell CE, Ives N, Stowe R. Monoamine oxidase B inhibitors for early
Parkinson's disease. Cochrane Database Syst Rev 2005;(3):CD004898.
(135) Presthus J, Berstad J, Lien K. Selegiline (1-deprenyl) and low-dose levodopa treatment of
Parkinson's disease. A double-blind crossover trial. Acta Neurol Scand 1987; 76(3):200-203.
(136) Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D et al. Double-blind,
randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease
patients. Mov Disord 2004; 19(8):916-923.
(137) Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K et al. Rasagiline-associated
motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
J Neurol Sci 2006; 248(1-2):78-83.
(138) Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T et al. Rasagiline improves
quality of life in patients with early Parkinson's disease. Mov Disord 2006; 21(5):616-623.
(139) Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson's
disease. Pharmacotherapy 2007; 27(12 Pt 2):174S-185S.
(140) Thorpy MJ, Adler CH. Parkinson's disease and sleep. Neurol Clin 2005; 23(4):1187-1208.
(141) Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist:
new possibilities for therapeutic applications? Clin Neurol Neurosurg 1992; 94 Suppl:S4-S6.
(142) Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson's disease. Cochrane Database
Syst Rev 2003;(1):CD003468.
(143) Sage JI, Mark MH. Pharmacokinetics of continuous-release carbidopa/levodopa. Clin
Neuropharmacol 1994; 17 Suppl 2:S1-S6.
(144) Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and
controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study.
The CR First Study Group. Eur Neurol 1997; 37(1):23-27.
(145) Dupont E, Andersen A, Boas J, Boisen E, Borgmann R, Helgetveit AC et al. Sustainedrelease
Madopar HBS compared with standard Madopar in the long-term treatment of de
novo parkinsonian patients. Acta Neurol Scand 1996; 93(1):14-20.
(146) Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC. Clinical experience
with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 1993;
43(4):677-681.
(147) Crosby NJ, Deane KH, Clarke CE. Beta-blocker therapy for tremor in Parkinson's disease.
Cochrane Database Syst Rev 2003;(1):CD003361.
(148) Claveria L, Vakil S, George C, et al. Oxprenolol in Parkinsonism. Journal of Clinical
Pharmacology 2007; 15:66-68.
(149) Brooks JO, Hoblyn JC. Neurocognitive costs and benefits of psychotropic medications in
older adults. J Geriatr Psychiatry Neurol 2007; 20(4):199-214.
(150) Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic
management of Parkinson's disease. Cochrane Database Syst Rev 2003;(2):CD003735.
(151) Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of
dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's
disease. A follow-up study of untreated patients. Brain 1992; 115 ( Pt 6):1701-1725.
(152) Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to druginduced
alterations in human consciousness. Brain Cogn 1995; 28(3):240-258.
(153) Hely MA, Morris JG, Reid WG, O'Sullivan DJ, Williamson PM, Rail D et al. The Sydney
Multicentre Study of Parkinson's disease: a randomised, prospective five year study
comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg
Psychiatry 1994; 57(8):903-910.
(154) Caraceni T, Musicco M. Levodopa or dopamine agonists, or deprenyl as initial treatment for
Parkinson's disease. A randomized multicenter study. Parkinsonism Relat Disord 2001;
7(2):107-114.
(155) Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced
dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;
41(2 ( Pt 1)):202-205.
(156) Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K. Impact of pramipexole
on the onset of levodopa-related dyskinesias. Mov Disord 2007; 22(9):1317-1319.
(157) Kostic VS, Marinkovic J, Svetel M, Stefanova E, Przedborski S. The effect of stage of
Parkinson's disease at the onset of levodopa therapy on development of motor
complications. Eur J Neurol 2002; 9(1):9-14.
231